title: A quantitative affinity-profiling system that reveals distinct CD4/CCR5 usage patterns among human immunodeficiency virus type 1 and simian immunodeficiency virus strains.
abstract: The affinity of human immunodeficiency virus (HIV) envelope for CD4 and CCR5 appears to be associated with aspects of R5 virus (virus using the CCR5 coreceptor) pathogenicity. However, entry efficiency results from complex interactions between the viral envelope glycoprotein and both CD4 and CCR5, which limits attempts to correlate viral pathogenicity with surrogate measures of envelope CD4 and CCR5 affinities. Here, we present a system that provides a quantitative and comprehensive characterization of viral entry efficiency as a direct interdependent function of both CD4 and CCR5 levels. This receptor affinity profiling system also revealed heretofore unappreciated complexities underlying CD4/CCR5 usage. We first developed a dually inducible cell line in which CD4 and CCR5 could be simultaneously and independently regulated within a physiologic range of surface expression. Infection by multiple HIV type 1 (HIV-1) and simian immunodeficiency virus isolates could be examined simultaneously for up to 48 different combinations of CD4/CCR5 expression levels, resulting in a distinct usage pattern for each virus. Thus, each virus generated a unique three-dimensional surface plot in which viral infectivity varied as a function of both CD4 and CCR5 expression. From this functional form, we obtained a sensitivity vector along with corresponding metrics that quantified an isolate's overall efficiency of CD4/CCR5 usage. When applied to viral isolates with well-characterized sensitivities to entry/fusion inhibitors, the vector metrics were able to encapsulate their known biological phenotypes. The application of the vector metrics also indicated that envelopes derived from elite suppressors had overall-reduced entry efficiencies compared to those of envelopes derived from chronically infected viremic progressors. Our affinity-profiling system may help to refine studies of R5 virus tropism and pathogenesis.
authors.affiliation: Division of Pediatric Infectious Diseases, David Geffen School of Medicine, UCLA, Los Angeles, California 90095, USA.
authors.forename: Samantha H
authors.initials: SH
authors.lastname: Johnston
authors.forename: Michael A
authors.initials: MA
authors.lastname: Lobritz
authors.forename: Sandra
authors.initials: S
authors.lastname: Nguyen
authors.forename: Kara
authors.initials: K
authors.lastname: Lassen
authors.forename: Shirley
authors.initials: S
authors.lastname: Delair
authors.forename: Filippo
authors.initials: F
authors.lastname: Posta
authors.forename: Yvonne J
authors.initials: YJ
authors.lastname: Bryson
authors.forename: Eric J
authors.initials: EJ
authors.lastname: Arts
authors.forename: Tom
authors.initials: T
authors.lastname: Chou
authors.forename: Benhur
authors.initials: B
authors.lastname: Lee
mesh_terms: D000345:Affinity Labels; D000818:Animals; D015704:CD4 Antigens / Q000235:genetics / Q000502:physiology*; D002460:Cell Line; D004441:Ecdysterone / Q000031:analogs & derivatives / Q000378:metabolism; D015497:HIV-1 / Q000502:physiology*; D006801:Humans; D055641:Mathematical Concepts; D008911:Minocycline / Q000378:metabolism; D019713:Receptors, CCR5 / Q000235:genetics / Q000502:physiology*; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000378:metabolism; D015302:Simian Immunodeficiency Virus / Q000502:physiology*; D053586:Virus Internalization
chemical_list: D000345:Affinity Labels; D015704:CD4 Antigens; D019713:Receptors, CCR5; D011993:Recombinant Fusion Proteins; D004441:Ecdysterone; C008999:ponasterone A; D008911:Minocycline
references.citation: Semin Immunol. 1998 Jun;10(3):187-94
references.pmid: 9653045
references.citation: J Leukoc Biol. 2006 Nov;80(5):965-72
references.pmid: 16923919
references.citation: AIDS Res Hum Retroviruses. 2002 Mar 20;18(5):353-62
references.pmid: 11897037
references.citation: AIDS Res Hum Retroviruses. 2004 Jan;20(1):111-26
references.pmid: 15000703
references.citation: J Infect Dis. 2005 Mar 15;191(6):866-72
references.pmid: 15717260
references.citation: PLoS Pathog. 2009 Apr;5(4):e1000377
references.pmid: 19360131
references.citation: Clin Infect Dis. 2007 Feb 15;44(4):591-5
references.pmid: 17243065
references.citation: J Infect Dis. 2003 Sep 15;188(6):864-72
references.pmid: 12964118
references.citation: Virology. 2005 Jul 5;337(2):384-98
references.pmid: 15916792
references.citation: J Virol. 2001 Nov;75(21):10073-89
references.pmid: 11581376
references.citation: J Exp Med. 2009 Jun 8;206(6):1273-89
references.pmid: 19487424
references.citation: J Infect Dis. 2006 Jul 15;194(2):238-46
references.pmid: 16779731
references.citation: J Virol. 2001 Apr;75(8):3568-80
references.pmid: 11264346
references.citation: J Virol. 1999 Feb;73(2):1655-60
references.pmid: 9882375
references.citation: Virology. 2004 Sep 15;327(1):16-25
references.pmid: 15327894
references.citation: J Virol. 2003 Aug;77(16):9069-73
references.pmid: 12885922
references.citation: J Virol. 2005 May;79(10):6089-101
references.pmid: 15857994
references.citation: J Virol. 2002 Jun;76(12):6277-92
references.pmid: 12021361
references.citation: Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16249-54
references.pmid: 12444251
references.citation: Blood. 2000 Sep 1;96(5):1638-45
references.pmid: 10961858
references.citation: J Infect Dis. 1994 May;169(5):968-74
references.pmid: 7909549
references.citation: J Virol. 2005 Jul;79(14):9006-18
references.pmid: 15994794
references.citation: J Virol. 2005 Jun;79(11):7121-34
references.pmid: 15890952
references.citation: Proc Natl Acad Sci U S A. 1999 Apr 27;96(9):5215-20
references.pmid: 10220446
references.citation: Virology. 2009 May 10;387(2):296-302
references.pmid: 19303620
references.citation: J Virol. 1997 Feb;71(2):883-90
references.pmid: 8995604
references.citation: Antimicrob Agents Chemother. 2007 Feb;51(2):566-75
references.pmid: 17116663
references.citation: J Virol. 2004 Oct;78(20):11130-41
references.pmid: 15452233
references.citation: J Virol. 2007 Aug;81(15):7885-93
references.pmid: 17507467
references.citation: AIDS Res Hum Retroviruses. 2002 May 20;18(8):567-76
references.pmid: 12036486
references.citation: AIDS Res Hum Retroviruses. 2001 Jul 1;17(10):925-35
references.pmid: 11461678
references.citation: J Infect Dis. 2003 May 1;187(9):1397-403
references.pmid: 12717620
references.citation: J Clin Invest. 1994 Nov;94(5):2060-7
references.pmid: 7962552
references.citation: Virology. 2000 Feb 15;267(2):237-46
references.pmid: 10662619
references.citation: J Virol. 2009 Nov;83(21):11005-15
references.pmid: 19692476
references.citation: Nat Med. 1999 May;5(5):535-41
references.pmid: 10229230
references.citation: Antivir Chem Chemother. 2005;16(6):339-54
references.pmid: 16329283
references.citation: Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14742-7
references.pmid: 9405683
references.citation: J Virol. 2007 Aug;81(15):8258-69
references.pmid: 17522224
references.citation: J Cell Biol. 2000 Oct 16;151(2):F9-14
references.pmid: 11038194
references.citation: Retrovirology. 2007 Dec 12;4:89
references.pmid: 18076768
references.citation: Curr HIV Res. 2005 Jan;3(1):53-60
references.pmid: 15638723
references.citation: J Virol. 1997 Feb;71(2):873-82
references.pmid: 8995603
references.citation: Virology. 2007 Feb 5;358(1):23-38
references.pmid: 16999983
references.citation: Virology. 2004 Mar 30;321(1):8-22
references.pmid: 15033560
references.citation: J Virol. 1999 Dec;73(12):9741-55
references.pmid: 10559284
references.citation: J Virol. 2007 Mar;81(5):2359-71
references.pmid: 17182681
references.citation: Virology. 2007 Apr 25;361(1):212-28
references.pmid: 17166540